Trametinib is currently approved for various cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, either as monotherapy or in combination with dabrafenib, a BRAF inhibitor, for improved therapeutic efficacy. This evidence concerns the gene BRAF and non-small cell lung carcinoma.